Synopsis: Aptus Pharma, Biogen Pharmachem Industries, and Dev Labtech Venture Limited announced bonus and stock split actions, aimed at improving liquidity, making shares more affordable, and attracting stronger investor interest this week.
Bonus shares are extra shares given free of cost to existing shareholders, usually from a company’s reserves. They are issued as a reward for investor trust and indicate strong financial health. While the total investment value remains the same, bonus issues increase the number of shares held, improving liquidity in the market.
A stock split works by dividing existing shares into smaller units, reducing their face value and increasing the total number of shares. This does not change the overall value of an investor’s holding, but makes the shares more affordable and easier to trade. Recently, many companies have announced such actions, reflecting financial strength and supporting greater investor participation. Here are the companies to watch in the coming week that have announced a bonus share and stock split:
With a market capitalization of Rs. 291.55 crore, the shares of Aptus Pharma Limited closed at Rs. 425 per equity share, down nearly 4.49 percent from its previous day’s close price of Rs. 445.
Aptus Pharma Limited has announced a bonus issue in a 3:2 ratio, granting shareholders three additional fully paid-up equity shares of Rs. 10 each for every two existing fully paid-up equity shares they hold. The record date for this is set for 12th May, 2026.
For example, if a shareholder owns 3,000 shares of Aptus Pharma Limited, they will receive 4,500 bonus shares, after this bringing their total holding to 7,500 shares after the 3:2 bonus issue.
Aptus Pharma Limited is an Indian pharmaceutical marketing and distribution company headquartered in Ahmedabad, Gujarat. Incorporated in 2010, it focuses on contract manufacturing of finished formulations across diverse therapeutic areas. The company became publicly listed on the BSE SME platform in September 2025 following a successful initial public offering (IPO) that underscored its rapid financial growth and expanding market reach.
Biogen Pharmachem Industries Limited
With a market capitalization of Rs. 40.62 crore, the shares of Biogen Pharmachem Industries Limited closed at Rs. 0.45 per equity share, down nearly 6.25 percent from its previous day’s close price of Rs. 0.48.
Biogen Pharmachem Industries Limited has announced a bonus issue in a 1:6 ratio, granting shareholders one additional fully paid-up equity share of Re. 1 each for every six existing fully paid-up equity shares they hold. The record date for this is set for 15th May, 2026.
For example, if a shareholder owns 3,000 shares of Biogen Pharmachem Industries Limited, they will receive 500 bonus shares, after this bringing their total holding to 3,500 shares after the 1:6 bonus issue.
Biogen Pharmachem Industries Limited is an Indian pharmaceutical and chemical manufacturing company engaged in producing active pharmaceutical ingredients (APIs), intermediates, and fine chemicals. The firm operates within India’s growing life sciences and specialty chemicals sectors, supplying raw materials to domestic and international pharmaceutical manufacturers.
Dev Labtech Venture Limited
With a market capitalization of Rs. 147.46 crore, the shares of Dev Labtech Venture Limited closed at Rs. 124.30 per equity share, rising nearly 1.97 percent from its previous day’s close price of Rs. 121.90.
Dev Labtech Venture Limited’s board decided to issue a stock split at a ratio of 1:2, meaning that each equity share’s face value of Rs. 10 will be divided into two equity shares with a share value of Rs. 5 each. The record date for this split is 15th May, 2026.
For example, if a shareholder owns 3,000 shares valued at Rs. 10 each in Dev Labtech Venture Limited, after the 1:2 stock split, their total holding will increase to 6,000 shares with a face value of Rs. 5 each. The value of the holding will remain unchanged.
Dev Labtech Venture Limited has also announced a bonus issue in a 1:1 ratio, granting shareholders one additional fully paid-up equity share of Rs. 5 each for every one existing fully paid-up equity share they hold. The record date for this is set for 15th May, 2026.
For example, if a shareholder owns 6,000 shares of Dev Labtech Venture Limited, they will receive 6,000 bonus shares, after this bringing their total holding to 12,000 shares after the 1:1 bonus issue.
Dev Labtech Venture Limited is an Indian company engaged in the manufacturing and sale of laboratory-grown diamonds and related equipment. Headquartered in Gujarat, it operates within the gem and jewelry sector, focusing on advanced technological processes for producing high-quality lab-grown diamonds used in both industrial and ornamental applications.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Leave a comment